Mirikizumab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Mirikizumab Usage And Synthesis

Uses

Mirikizumab (LY3074828) is a humanized IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23 (IL-23). Mirikizumab binds to human and monkey IL-23 with high affinity, with Kd values of 21 pM and 55 pM, respectively. By inhibiting the binding of IL-23 to IL-23R, Mirikizumab modulates the immune response and holds potential for research in ulcerative colitis and Crohn's disease[1][2].

in vivo

References

[1] Jefremow A, et al. Some are More Equal: Targeting IL 12 and 23 in IBD - A Clinical Perspective. Immunotargets Ther. 2020 Nov 26;9:289-297.
[2] Steere B, et al. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. Steere B, Beidler C, Martin A, Bright S, Kikly K, Benschop RJ. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J Pharmacol Exp Ther. 2023 Nov;387(2):180-187. DOI:10.1124/jpet.122.001512

Mirikizumab(1884201-71-1)Related Product Information

• Secukinumab
• Ixekizumab
• Briakinumab
• Brazikumab
• ibritumomab tiuxetan
• Ustekinumab
• guselkumab
• Evolocumab
• Oleclumab
• Brodalumab